Open AccessDalpiciclib Extends Progression‐Free Survival in HR +/ HER2 – Advanced Breast Cancer
Publication year - 2021
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1002/onco.13865
Subject(s) - medicine , fulvestrant , oncology , clinical endpoint , breast cancer , cancer , progression free survival , metastatic breast cancer , overall survival , clinical trial , tamoxifen
The phase III DAWNA‐1 trial met its primary endpoint of improved progression‐free survival with dalpiciclib added to fulvestrant in previously treated HR‐positive, HER2‐negative advanced breast cancer, signaling a new option for combination therapy with a CDK4/6 inhibitor and endocrine therapy.